share_log

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Coeptis Therapeutics Executes Binding Letter of Intent to Acquire Ai-powered Marketing Solutions for Biotech, Pharmaceutical and Other Industries

Coeptis Therapeutics執行了收購生物技術、藥品和其他行業的人工智能營銷解決方案的有約束力意向書
Coeptis Therapeutics ·  12/03 13:00

The Acquisition of NexGenAI Affiliates Network Expands Company's Capabilities and Drives Innovation, Operational Efficiency, and Opportunity for Growth

收購NexGenAI附屬網絡拓展了公司的能力,推動創新、運營效率和增長機會

WEXFORD, Pa. , Dec. 3, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases, is pleased to announce the execution of a Binding Letter of Intent for the acquisition of NexGenAI Affiliates Network, a platform developed by NexGenAI Solutions Group and its affiliates ("NexGenAI") that offers AI-powered marketing software and robotic process automation ("RPA") capabilities. By integrating AI-powered solutions and RPA tools, Coeptis not only enhances its operational efficiency but also positions itself to leverage these advanced technologies for broader applications, creating new opportunities for growth while maintaining its primary focus on biopharmaceutical innovation.

賓夕法尼亞州韋克斯福德,2024年12月3日 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (納斯達克: COEP) ("公司"或"Coeptis"), 是一家開發創新電芯治療平台以治療癌症、自身免疫性疾病和感染性疾病的生物製藥公司,欣然宣佈與NexGenAI Solutions Group及其附屬公司("NexGenAI")簽署了收購NexGenAI附屬網絡的具有約束力的意向書。該平台提供人工智能驅動的營銷軟件和機器人過程自動化("RPA")能力。通過整合人工智能驅動的解決方案和RPA工具,Coeptis不僅提高了其運營效率,還爲更廣泛的應用利用這些愛文思控股技術,創造新的增長機會,同時保持其對生物製藥創新的重點。

big

NexGenAI has developed a suite of innovative marketing tools that utilize AI and RPA to optimize campaigns, streamline workflows, and generate actionable insights. By acquiring these assets, Coeptis will bring these state-of-the-art solutions to companies seeking to overcome marketing challenges in competitive and highly regulated sectors, particularly in the biotech, pharmaceutical and multi-level marketing ("MLM") industries. These tools will help companies run smarter, more efficient marketing campaigns, saving time and resources while staying compliant with strict regulations.

NexGenAI開發了一套創新的營銷工具,利用人工智能和RPA來優化活動、簡化工作流程,並生成可操作的見解。通過收購這些資產,Coeptis將把這些先進的解決方案帶給在競爭激烈和高度監管行業中尋求克服營銷挑戰的公司,特別是在生物科技、藥品和多級營銷("MLM")行業。這些工具將幫助公司更智能、更有效地運行營銷活動,同時節省時間和資源,保持遵守嚴格的法規。

Dave Mehalick, President and CEO of Coeptis Therapeutics commented, "We are excited to integrate NexGenAI Affiliates Network and groundbreaking AI and RPA-driven tools into our offerings. In industries like biotech, pharma, and MLM, where competition is so high and regulatory challenges are complex, having advanced tools to optimize marketing, streamline operations, and drive measurable results is critical."

Coeptis Therapeutics的總裁兼首席執行官Dave Mehalick評論道:"我們很高興將NexGenAI附屬網絡和開創性的人工智能和RPA驅動工具整合到我們的產品中。在生物科技、藥品和多級營銷等競爭激烈且監管挑戰複雜的行業中,擁有先進工具來優化營銷、簡化運營和推動可衡量的結果至關重要。"

Anshuman Dash, Lead Advisory behind the development of NexGenAI Affiliates Network commented, "The integration of NexGenAI's innovative AI-powered marketing solutions with Coeptis Therapeutics' forward-thinking approach marks a transformative step forward. This acquisition not only validates the cutting-edge technology we've developed but also aligns with Coeptis' mission to drive innovation in highly regulated industries. Together, we aim to revolutionize marketing strategies and operational efficiencies, ultimately delivering greater value to our partners and the industries we serve."

NexGenAI附屬網絡開發的首席顧問Anshuman Dash評論道:"NexGenAI的創新人工智能驅動的營銷解決方案與Coeptis Therapeutics前瞻性方法的整合標誌着向前邁出了一步。這次收購不僅驗證了我們開發的前沿技術,還與Coeptis推動高度監管行業創新的使命相一致。我們共同致力於革新營銷策略和運營效率,最終爲我們的合作伙伴和我們所服務的行業創造更大的價值。"

About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively "Coeptis"), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer and infectious diseases. The Company is headquartered in Wexford, PA. For more information on Coeptis visit .

關於Coeptis Therapeutics Holdings,Inc。
Coeptis Therapeutics Holdings公司及其子公司Coeptis Therapeutics和Coeptis Pharmaceuticals(統稱爲「Coeptis」)是一家生物製藥公司,開發用於癌症、自身免疫和傳染性疾病的創新細胞治療平台,有可能顛覆傳統的治療模式並改善患者的預後。Coeptis的產品組合和權益主要來自Deverra Therapeutics許可的資產,包括異基因細胞免疫療法平台和DVX201,這是一種臨床階段的未修改的自然殺傷細胞療法技術。此外,Coeptis正在開發一種來自匹茲堡大學的通用多抗原CAR T技術(SNAP-CAR),以及GEAR細胞治療和伴隨診斷平台,該平台由Coeptis與VyGen-Bio和卡羅林斯卡學院的領先醫學研究人員共同開發。Coeptis的商業模式旨在通過許可協議、外部許可協議和共同開發關係,以及與戰略合作伙伴建立戰略合作關係,來最大化其現有產品組合和權益的價值,特別是那些針對癌症和傳染性疾病的產品。該公司總部位於賓夕法尼亞州的Wexford。有關Coeptis的更多信息,請訪問。

About NexGenAI:
NexGenAI Holding Group Inc., along with its majority-owned subsidiary NexGenAI Solutions Group, Inc., has developed a proprietary suite of advanced tools that power the NexGenAI Affiliates Network platform. These tools, featuring AI-driven marketing software and robotic process automation capabilities, are designed to optimize campaigns, streamline operations, and provide actionable, data-driven insights. NexGenAI's platform provides cutting-edge AI-driven solutions that revolutionize business operations across various sectors. By leveraging artificial intelligence, NexGenAI empowers companies to automate processes, optimize efficiency, and drive sustainable growth. For more information on NexgenAI go to nexgenai.io.

關於NexGenAI:
NexGenAI控股集團公司及其控股子公司NexGenAI解決方案集團公司,開發了一套專有的先進工具,支持NexGenAI附屬網絡平台。這些工具具有人工智能驅動的營銷軟件和機器人流程自動化能力,旨在優化活動、簡化運營,並提供可行的以數據爲驅動的洞察。NexGenAI的平台提供尖端的人工智能驅動解決方案,徹底改革各個行業的業務運營。通過利用人工智能,NexGenAI使公司能夠自動化流程、優化效率,並推動可持續增長。有關NexGenAI的更多信息,請訪問nexgenai.io。

Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the risk that the integration of the Deverra licensed assets will disrupt current plans and operations of the Company; (3) the inability to recognize the anticipated benefits of the newly-licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (4) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable regulatory authorities; (5) costs related to integrating the newly-licensed Deverra assets and pursuing the contemplated asset development paths; (6) changes in applicable laws or regulations; (7) the possibility that the Company may be adversely affected by other economic, business, and/or competitive factors; and (8) the impact of the global COVID-19 pandemic on any of the foregoing risks and other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission (the "SEC"). The foregoing list of factors is not exclusive. All forward-looking statements are subject to significant uncertainties and risks including, but not limited, to those risks contained or to be contained in reports and other filings filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings made or to be made with the SEC, which are available for review at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof unless required by applicable laws, regulations, or rules.

關於前瞻性聲明的警告
本新聞稿及我們管理層在此處所述的聲明包含或可能包含「前瞻性陳述」(根據《1933年證券法修正案》第27A條和《1934年證券交易法修正案》第21E條的定義)。前瞻性陳述包括涉及我們的計劃、目標、目標、戰略、未來事件或業務表現以及基本假設的陳述,以及與歷史事實無關的其他陳述。當我們使用諸如「可能」,「將」,「打算」,「應該」,「相信」,「期望」,「預計」,「項目」,「估計」或類似表達式(不僅與歷史事實有關)時,我們正在進行前瞻性陳述。前瞻性陳述不能保證未來業績,並涉及重大風險和不確定性,可能導致實際結果與前瞻性陳述中討論的我們的期望在很大程度上存在實質性差異。可能導致這種差異的因素包括但不限於:(1)無法在納斯達克資本市場上維持公司證券的上市狀態;(2)來自Deverra許可的資產整合可能會破壞公司目前的計劃和運營;(3)無法實現新獲得的資產的預期收益可能受到競爭等因素的影響,公司的經濟增長和管理增長以及僱傭和留用主要員工的能力;(4)尚在開發中的公司產品或新獲得的資產在臨床試驗中失敗或未獲得美國食品藥品監督管理局或其他適用監管機構的批准;(5)與整合新獲得的Deverra資產和追求擬議資產開發路徑相關的成本;(6)適用法律或法規的變化;(7)公司可能受到其他經濟、商業和/或競爭因素的不利影響的可能性;以及(8)全球COVID-19大流行對上述風險以及與該公司在美國證券交易委員會(SEC)的文件中所識別的其他風險和不確定性的影響。上述因素的清單並非詳盡無遺。所有前瞻性陳述都存在重大不確定性和風險,包括但不限於在美國證券交易委員會提交或將要提交的報告和其他文件中所包含的那些風險。因此,出於上述和其他原因,投資者應當注意不要過度依賴本新聞稿中的任何前瞻性陳述。其他因素將在公司向SEC提交的文件中進行討論,這些文件可在www.sec.gov進行查閱。除非適用法律、法規或規則要求,否則我們不承諾公開修訂這些前瞻性陳述,以反映此後產生的事件或情況。

Contacts
Coeptis Therapeutics, Inc.
IR@coeptistx.com

聯繫方式
Coeptis Therapeutics,Inc。
IR@coeptistx.com

SOURCE Coeptis Pharmaceuticals, Inc.

來源 Coeptis 藥品公司。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論